Galecto (GLTO) Competitors $3.43 -0.51 (-12.94%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$3.45 +0.02 (+0.47%) As of 03/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLTO vs. LSTA, NNVC, BIVI, EGRX, LSB, LPCN, MTEX, SNTI, CGTX, and INABShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Lisata Therapeutics (LSTA), NanoViricides (NNVC), BioVie (BIVI), Eagle Pharmaceuticals (EGRX), Lakeshore Biopharma (LSB), Lipocine (LPCN), Mannatech (MTEX), Senti Biosciences (SNTI), Cognition Therapeutics (CGTX), and IN8bio (INAB). These companies are all part of the "pharmaceutical products" industry. Galecto vs. Lisata Therapeutics NanoViricides BioVie Eagle Pharmaceuticals Lakeshore Biopharma Lipocine Mannatech Senti Biosciences Cognition Therapeutics IN8bio Galecto (NASDAQ:GLTO) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, community ranking, analyst recommendations, valuation, media sentiment and institutional ownership. Do institutionals and insiders hold more shares of GLTO or LSTA? 14.2% of Galecto shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 11.9% of Galecto shares are owned by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer GLTO or LSTA? Galecto received 18 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 93.33% of users gave Lisata Therapeutics an outperform vote while only 60.38% of users gave Galecto an outperform vote. CompanyUnderperformOutperformGalectoOutperform Votes3260.38% Underperform Votes2139.62% Lisata TherapeuticsOutperform Votes1493.33% Underperform Votes16.67% Does the media prefer GLTO or LSTA? In the previous week, Galecto had 6 more articles in the media than Lisata Therapeutics. MarketBeat recorded 8 mentions for Galecto and 2 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.43 beat Galecto's score of 0.11 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Galecto Neutral Lisata Therapeutics Positive Which has stronger valuation and earnings, GLTO or LSTA? Lisata Therapeutics has higher revenue and earnings than Galecto. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectoN/AN/A-$38.35M-$18.61-0.18Lisata Therapeutics$1M20.14-$20.84M-$2.40-0.97 Do analysts prefer GLTO or LSTA? Galecto currently has a consensus price target of $10.00, indicating a potential upside of 191.55%. Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 542.12%. Given Lisata Therapeutics' higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Galecto.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, GLTO or LSTA? Galecto has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Is GLTO or LSTA more profitable? Lisata Therapeutics' return on equity of -51.19% beat Galecto's return on equity.Company Net Margins Return on Equity Return on Assets GalectoN/A -76.96% -66.59% Lisata Therapeutics N/A -51.19%-45.16% SummaryLisata Therapeutics beats Galecto on 8 of the 14 factors compared between the two stocks. Remove Ads Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.53M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-0.187.2023.1419.03Price / SalesN/A226.01384.1193.17Price / CashN/A65.6738.1634.64Price / Book0.126.476.954.33Net Income-$38.35M$141.90M$3.20B$247.06M7 Day Performance-43.77%-3.20%-2.28%-0.37%1 Month Performance-21.69%-5.64%2.88%-3.85%1 Year Performance-82.41%-7.47%10.87%1.27% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto3.0751 of 5 stars$3.43-12.9%$10.00+191.5%-82.4%$4.53MN/A-0.1840Short Interest ↑LSTALisata Therapeutics3.0647 of 5 stars$2.38-0.4%$15.00+530.3%-27.7%$20.52M$1M-0.9530Short Interest ↓Gap DownNNVCNanoViricidesN/A$1.31+6.5%N/A+7.1%$20.49MN/A-1.8220BIVIBioVie2.8889 of 5 stars$1.10+1.9%$3.00+172.7%+102.4%$20.30MN/A-0.1110Short Interest ↓News CoverageEGRXEagle PharmaceuticalsN/A$1.50+15.4%N/A-81.1%$19.48M$257.55M0.00100LSBLakeshore Biopharma1.5349 of 5 stars$2.05+2.3%N/AN/A$19.03M$672.27M0.00773Positive NewsGap DownLPCNLipocine2.1241 of 5 stars$3.50+4.5%$10.00+185.7%-36.5%$18.72M$7.92M-4.6110MTEXMannatech0.5404 of 5 stars$9.92-3.0%N/A+9.1%$18.70M$121.55M-12.25250Earnings ReportAnalyst ForecastGap UpSNTISenti Biosciences3.5418 of 5 stars$3.87+10.9%$10.00+158.4%-14.6%$18.69M$2.56M-0.254Short Interest ↓CGTXCognition Therapeutics3.7723 of 5 stars$0.45-0.1%$8.30+1,757.2%-75.2%$18.57MN/A-0.4620Short Interest ↓Analyst RevisionINABIN8bio3.2238 of 5 stars$0.23+0.4%$6.75+2,884.1%-82.8%$18.38MN/A-0.3020Short Interest ↑Gap Up Remove Ads Related Companies and Tools Related Companies Lisata Therapeutics Competitors NanoViricides Competitors BioVie Competitors Eagle Pharmaceuticals Competitors Lakeshore Biopharma Competitors Lipocine Competitors Mannatech Competitors Senti Biosciences Competitors Cognition Therapeutics Competitors IN8bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLTO) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLTO Stock Free GLTO Stock Alerts